Scoop: With its NDA in lim­bo, Iron­shore ex­ecs shut­tered the AD­HD biotech

A year ago Iron­shore Phar­ma­ceu­ti­cals ex­ecs trum­pet­ed the news that they had lined up $200 mil­lion in fi­nanc­ing to launch a new AD­HD drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.